Apr. 14, 2020

Teijin Pharma Limited
Teijin Healthcare Limited

Teijin Pharma Limited and Teijin Healthcare Limited, the core companies of the Teijin Group’s healthcare business, have designated the respiratory field as a priority business sector and have been supporting patients' quality of life for many years with pharmaceuticals and home healthcare devices, responding to diverse needs in Japan.

(1) Pharmaceuticals

In response to a request from Japan’s Ministry of Health, Labor and Welfare on March 9, Teijin Pharma is preparing to supply ciclesonide, a corticosteroid for asthma treatment, which the company manufactures and sells in Japan under license from a foreign-based entity, for study as a possible therapeutic agent for COVID-19 (see here for details). The company is now in contact with the licensor to discuss the way for the increased demand for the supply.
Teijin Pharma has confirmed that its delivery of ciclesonide to bronchial asthma patients now using the drug will continue uninterrupted. Inhaled corticosteroid, known generically as ciclesonide, is a metered-dose aerosol approved for adults and children as a therapeutic drug for bronchial asthma.

(2) Medical equipment

Separately, Teijin Pharma and Teijin Healthcare are preparing to increase production of a proprietary oxygen concentrator. Also, they are in talks with the manufacturer of a non-invasive positive-pressure ventilation (NPPV) device that the two firms currently handle and wish to supply on an expanded basis. The oxygen concentrator and NPPV device both can be used to provide artificial-respiration support to COVID-19 patients in Japan.

The oxygen concentrator is used for home oxygen therapy (HOT), which enables oxygen-deficient patients to inhale oxygen safely at home. The NPPV device provides ventilation assistance via a mask and discharges carbon dioxide as it accumulates in the lungs, eliminating the need for tracheal intubation or a tracheotomy.

Back to 2020 News

Page Top